No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Where Will Viking Therapeutics Be in 3 Years?
Will Pfizer Will Acquire Altimmune or Viking Therapeutics After Its Obesity Pill Setback?
Viking Among Notable Gainers as Pfizer Raises Deal Prospects
Cantor Fitzgerald Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Cuts Target Price to $104
Truist Financial Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Announces Target Price $75
Cantor Fitzgerald Initiates Coverage On Viking Therapeutics With Overweight Rating, Announces Price Target of $104